Lupin Limited, a Mumbai, India-headquartered pharmaceutical company, has completed its previously announced acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. Lupin had announced the acquisition in July 2015. The acquisition enhances Lupin's scale in the US generics market and also broadens Lupin's pipeline in dermatology, controlled substance products, and other niche generics.

The move also provides Lupin with an US-based manufacturing and research organization that would complement Lupin's Coral Springs, Florida-based R&D center for inhalation. GAVIS's New Jersey-based manufacturing facility will be Lupin's first manufacturing site in the US.

New Jersey-based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. GAVIS has 62 abbreviated new drug applications filings pending approval with the US Food and Drug Administration and a pipeline of more than 65 products under development. Seventy-two of these filings pending approvals represent niche dosage forms with 18 Paragraph IVs and eight first-to-file (FTF) products.

The combined company has a portfolio of over 120 in-market products, over 185 cumulative filings pending approval, and a pipeline of products under development for the US. Lupin has 37 FTF products, which includes 17 exclusive FTF opportunities. Lupin and Gavis combined would now have over 45 FTFs.

Source: Lupin